Merck & Co., Inc. (NYSE:MRK) Shares Sold by Panoramic Investment Advisors LLC

Panoramic Investment Advisors LLC reduced its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 19.9% during the 4th quarter, Holdings Channel reports. The fund owned 4,230 shares of the company’s stock after selling 1,050 shares during the quarter. Panoramic Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $461,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Ascent Wealth Partners LLC grew its position in Merck & Co., Inc. by 0.5% in the 4th quarter. Ascent Wealth Partners LLC now owns 16,579 shares of the company’s stock worth $1,807,000 after purchasing an additional 89 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its holdings in shares of Merck & Co., Inc. by 1.9% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 4,811 shares of the company’s stock valued at $524,000 after acquiring an additional 92 shares in the last quarter. Bell Bank boosted its holdings in shares of Merck & Co., Inc. by 1.0% in the fourth quarter. Bell Bank now owns 9,235 shares of the company’s stock valued at $1,007,000 after acquiring an additional 92 shares in the last quarter. Prosperity Financial Group Inc. boosted its holdings in shares of Merck & Co., Inc. by 2.9% in the second quarter. Prosperity Financial Group Inc. now owns 3,365 shares of the company’s stock valued at $388,000 after acquiring an additional 95 shares in the last quarter. Finally, Bath Savings Trust Co boosted its holdings in shares of Merck & Co., Inc. by 1.8% in the fourth quarter. Bath Savings Trust Co now owns 5,539 shares of the company’s stock valued at $604,000 after acquiring an additional 98 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a report on Friday, February 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, March 27th. StockNews.com upgraded shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. TheStreet cut shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Finally, Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $129.71.

View Our Latest Stock Analysis on MRK

Merck & Co., Inc. Trading Down 0.2 %

Shares of NYSE:MRK traded down $0.21 during mid-day trading on Wednesday, hitting $130.14. The stock had a trading volume of 3,605,235 shares, compared to its average volume of 8,636,100. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. The company has a market cap of $329.60 billion, a PE ratio of 929.50, a P/E/G ratio of 0.52 and a beta of 0.38. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $133.10. The company’s 50 day moving average is $125.45 and its 200-day moving average is $113.20.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The company had revenue of $14.63 billion during the quarter, compared to the consensus estimate of $14.49 billion. During the same quarter in the prior year, the firm earned $1.62 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. On average, sell-side analysts predict that Merck & Co., Inc. will post 8.59 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a $0.77 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 2.37%. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the sale, the insider now owns 19,569 shares in the company, valued at approximately $2,443,972.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now owns 19,569 shares in the company, valued at approximately $2,443,972.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.